BridgeMD
A Phase 1/2a Study of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies
EU CTIS ID: 2025-523547-35-00
What this study is testing
To find out if BMS-986523 is safe and tolerable and to figure out the best dose and schedule for using BMS-986523 alone or with pembrolizumab, cetuximab, or gemcitabine plus nab-paclitaxel in participants with advanced solid malignancies that have KRAS alterations.
- Phase I and Phase II (Integrated)- First administration to humans
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known KRAS alteration (mutation or amplification): Part 1A: All tumor types (Arms A and B); Part 2A: NSCLC, CRC, and PDAC (Arm C); Part 1B: NSCLC (Arm D), CRC (Arm E), and PDAC (Arm F).
- Participants should have previously received, be ineligible for, or declined (after having been provided adequate information to make an informed decision) select standard of care treatments depending on their assigned study arm.
You likely can't join if
- Untreated central nervous system (CNS) metastases.
- Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
- Prior treatment with a (K)RAS directed therapy including approved treatments and investigational agents.
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.